Current evidence and the emerging role of eltrombopag in severe aplastic anemia
Acquired aplastic anemia (AA) is characterized by a reduced stem cell reserve. Several preclinical studies have confirmed the beneficial effect of thrombopoietin (TPO) on the expansion and maintenance of hematopoietic stem cells (HSCs). Thus, TPO receptor agonists seem to be an ideal therapeutic age...
Main Authors: | Beatrice Drexler, Jakob Passweg |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-03-01
|
Series: | Therapeutic Advances in Hematology |
Online Access: | https://doi.org/10.1177/2040620721998126 |
Similar Items
-
Eltrombopag for the treatment of aplastic anemia: current perspectives
by: Lum SH, et al.
Published: (2016-09-01) -
Pathogenesis of Acquired Aplastic Anemia and the Role of the Bone Marrow Microenvironment
by: Michael Medinger, et al.
Published: (2018-12-01) -
Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
by: Akiko Konishi, et al.
Published: (2019-01-01) -
Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States
by: Tremblay G, et al.
Published: (2019-11-01) -
Eltrombopag treatment of a dog with idiopathic aplastic pancytopenia
by: Darren Kelly, et al.
Published: (2020-03-01)